Different starting doses of enarodustat for anemia in kidney disease
Treatments studied
Part of Blood & lymphatic, Kidney & urinary clinical trials.
This study tests different starting doses of a pill called enarodustat to see which works best for anemia in people with chronic kidney disease who are not on dialysis. It aims to help raise red blood cell counts and reduce the need for injections.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You weigh between 45 and 100 kg (about 99 to 220 pounds).
- You have chronic kidney disease (stage 3-5) and are not on dialysis.
- Your hemoglobin (a measure of anemia) is between 70 and 100 g/L if you haven't used ESA injections recently, or between 100 and 120 g/L if you are currently on ESA therapy.
- You are willing to use contraception if you are a woman of childbearing age.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an oral medication (AND017) for anemia caused by chronic kidney disease. It aims to improve red blood cell levels without needing dialysis or current anemia treatments.
This study tests a new once-monthly injection called pegmolesatide for anemia in people with kidney disease on dialysis who are already taking roxadustat. It aims to see if switching to this injection can keep hemoglobin levels stable and reduce the need for transfusions.
This trial tests enarodustat, a pill for anemia, in people with chronic kidney disease who are not on dialysis. It aims to see if it can safely raise hemoglobin levels.
This study tests a daily pill that helps people with chronic kidney disease and anemia make more red blood cells, which may reduce the need for other anemia treatments. It is for patients who are not on dialysis and do not plan to start dialysis or have a kidney transplant within the next six months.
This trial tests whether a new drug called enarodustat, when combined with cyclosporine, can improve blood cell counts better than cyclosporine alone in people with transfusion-dependent non-severe aplastic anemia. If you qualify, you might need fewer transfusions and feel better overall.
This study tests a new drug called Efepoetin Alfa to treat anemia in people with chronic kidney disease who are on dialysis. The goal is to see if it can safely raise red blood cell levels and reduce the need for other anemia treatments.
Hear when a new Renal Anemia in Non-dialysis Chronic Kidney Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.